Milestone Pharmaceuticals Announces Pricing of Public Offering to Advance Innovative Cardiovascular Medicines
MONTREAL and CHARLOTTE, N.C. Feb.29, 2024 - Milestone Pharmaceuticals Inc.(Milestone) (Nasdaq: MIST), a biopharmaceutical company specializing in the development and commercialization of groundbreaking cardiovascular medications, has recently declared the pricing of its underwritten public offering.The offering consists of 16,666,667 common shares at a public offering price of $1.50 per share, as well as pre-funded warrants to purchase 3,333,333 common shares at a public offering price of $1.49 per pre-funded warrant.This move is expected to generate approximately $30.0 million in proceeds for Milestone, of which the underwriters have an option to purchase an additional 3,000,000 common shares.The financing is anticipated to close on or around March 4, 2024, contingent upon fulfilling customary closing conditions.
Milestone Pharmaceuticals is a renowned establishment dedicated to addressing the unmet needs within the cardiovascular treatment landscape.This recent public offering will provide the company with additional funds to advance its pipeline of innovative cardiovascular medicines.With an emphasis on developing groundbreaking therapies, Milestone aims to improve patient care and revolutionize the treatment options available for cardiovascular diseases.
The funding generated from this public offering is a significant achievement for Milestone’s ongoing mission.The company’s vision is to transform the treatment landscape by developing unique medicines that target specific cardiovascular conditions and improve patients’ quality of life.By focusing on unmet medical needs, Milestone aspires to usher in a new era of pharmaceutical solutions that address cardiovascular diseases more effectively.
The public offering comprises the issuance of 16,666,667 common shares, with each share priced at $1.50.Additionally, pre-funded warrants are being offered to purchase 3,333,333 common shares at $1.49 per warrant.The inclusion of pre-funded warrants enables investors to exercise their right to purchase common shares at a slightly reduced price, resulting in a lower overall investment cost.This structure is designed to attract potential shareholders and foster a diversified investor base.
The expected proceeds of approximately $30.0 million from this offering demonstrate the confidence and support of investors in the potential of Milestone Pharmaceuticals.The funds will primarily be directed towards accelerating the development and commercialization of the company’s promising cardiovascular medicines.It will also help the company engage in robust research and development activities, initiate clinical trials, and further expand its commercialization capabilities.
Moreover, Milestone Pharmaceuticals has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 common shares at the public offering price, excluding underwriting commissions.This provision allows the company to potentially raise additional funds if market demand warrants and offers further flexibility to support its growth initiatives in the cardiovascular space.
The closing of this public offering is contingent upon the fulfillment of customary closing conditions.The company is optimistic about the successful completion of the financing, and upon closure, Milestone Pharmaceuticals will be well-positioned to advance its innovative cardiovascular medicines, bringing hope and relief to patients afflicted by cardiovascular diseases.
In conclusion, Milestone Pharmaceuticals’ recently announced underwritten public offering signifies a major milestone for the company’s mission to revolutionize cardiovascular treatment.The pricing of common shares and pre-funded warrants will provide Milestone with substantial funding to support the development and commercialization of its innovative cardiovascular medicines.The expected proceeds of approximately $30.0 million, along with the option to purchase additional common shares, showcase the commitment of investors to the potential of Milestone’s groundbreaking therapies.With a focus on addressing unmet medical needs, Milestone Pharmaceuticals aims to transform patient care and improve outcomes in the realm of cardiovascular diseases.
Comments